Mumbai: Swiss pharma giant, Novartis, has announced having successfully
completed the European Union''s ''mutual recognition procedure'' (MRP) in 14
countries for its cardiac drug Diovan (valsartan) for the treatment of heart
an anti-hypertensive agent, is now indicated as a potentially life-saving
therapy for those at risk of a recurrent heart attack or other serious outcomes
such as cardiovascular mortality, hospitalisation for heart failure, resuscitated
cardiac arrest or stroke. Diovan is also being evaluated by EU regulatory
authorities for people with heart failure.
most widely prescribed ARB globally, Diovan provides a unique range of benefits
to patients with cardiovascular disease that is unlike any other agent of
its class," said Joerg Reinhardt, head of development, Novartis Pharma
AG. "Already trusted as a highly effective
and powerful high blood pressure agent, physicians can now prescribe Diovan
to help reduce mortality in patients who have suffered a heart attack."